Events and Presentations
Presentations and Posters
| Date | Title | Format |
|---|---|---|
|
Sep 18, 2021
|
ESMO Congress 2021: Efficacy and Safety of Poziotinib in Treatment-naïve NSCLC Harboring HER2 exon 20 Mutations: A Multinational Phase 2 Study (ZENITH20-4)
|
|
|
Sep 09, 2021
|
Current Corporate Presentation
|
Current Corporate Presentation 660.2 KB
|
|
Jun 04, 2021
|
2021 ASCO Annual Meeting: CNS activity of poziotinib in NSCLC with exon 20 insertion mutations
|
|
|
Apr 10, 2021
|
Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutations
|
|
|
Mar 05, 2021
|
38th Annual Miami Breast Cancer Conference: Interim safety evaluation of same-day dosing of eflapegrastim in patients with early-stage breast cancer (ESBC) receiving docetaxel and cyclophosphamide (TC)
|
|
|
Mar 02, 2021
|
ESMO TAT Virtual Congress 2021: Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
|
Upcoming Event
| Date | Title |
|---|---|
|
Sep 29, 2021
1:20 PM EDT
|
Archived Events
| Date | Title |
|---|---|
|
Aug 12, 2021
1:30 PM PDT
|
|
|
Jun 16, 2021
1:30 PM EDT
|
|
|
Jun 3, 2021
9:30 AM EDT
|
|
|
May 13, 2021
1:30 PM PDT
|
|
|
Mar 30, 2021
1:30 PM PDT
|
|
|
Feb 11, 2021
4:00 PM EST
|
|
|
Jan 21, 2021
1:00 PM EST
|
|
|
Jan 14, 2021
1:45 PM EST
|
|
|
Jan 11, 2021
6:00 AM EST
|
|
|
Dec 22, 2020
1:30 PM PST
|
View Presentation 478.3 KB
|
|
Nov 18, 2020
2:20 PM EST
|
|
|
Nov 16, 2020
2:40 PM EST
|
|
|
Nov 4, 2020
1:30 PM PST
|